Drug Trial Radar · NCT04399837
A Study to Test Whether BI 655130 (Spesolimab) Prevents Flare-ups in Patients With Generalized Pustular Psoriasis
Last checked: Nov 20, 2026Latest source record: Oct 20, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
123
Actual
Start
Jun 4, 2020
Primary completion
Nov 23, 2022
Study completion Nov 23, 2022
Sponsor
- Lead sponsor
- Boehringer IngelheimBoehringer Ingelheim
- Sponsor type
- Industry
- First posted
- May 22, 2020
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a study in adolescents and adults with Generalized Pustular Psoriasis (GPP). People between 12 and 75 years old can take part in the study. The study is open to people who had GPP flare-ups in the past but whose skin is clear or almost clear when they join the study. The purpose of the study is to test 3 different doses of a medicine called spesolimab and to see whether it helps to prevent GPP flare-ups. Participants are put into 4 groups by chance. Three groups get different doses of spesolimab. The fourth group gets a placebo. Placebo looks like spesolimab but does not contain any medicine. Spesolimab and placebo are given as an injection under the skin. Participants are in the study for about 1 year and 4 months. During this time, they visit the study site about 15 times. For the first 11 months, participants get spesolimab or placebo injections every month. At the study visits, the doctors check participants' skin for signs of a new GPP flare-up. The doctors also check the general health of the participants. If a participant has a GPP flare-up during the study, more visits may be necessary. In case of a flare-up, participants get a dose of spesolimab as an infusion into a vein.
Conditions
- Generalized Pustular Psoriasis
Interventions
SpesolimabDrug
Solution for injection
PlaceboDrug
Solution for injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to First Generalized Pustular Psoriasis (GPP) FlareTime frame: GPPGA was regularly assessed at baseline (Week 1) and up to Week 48 (at Week 4, 8, 12, 16, 20, 24, 28, 32, 36, 40, 44, 48). Patients could come to site for flare confirmation anytime as unscheduled visit. Visit window was ±7 days.
Locations
72 sites in 23 countries. Site status is shown where the registry gives one.
Oakland Hills Dermatology
Auburn Hills, Michigan
Washington University School of Medicine
St Louis, Missouri
Buenos Aires Skin S.A.
CABA, Argentina
Hospital Italiano de Buenos Aires
CABA, Argentina
Brussels - UNIV Saint-Luc
Brussels, Belgium
Clínica Dermacross S.A.
Vitacura, Chile
Sun yet-sen Memorial Hospital, Sun yet-sen Univesity
Guangzhou, China
The Second Affiliated Hospital Zhejiang University School of Medicine
Hangzhou, China
Shanghai Skin Disease Hospital
Shanghai, China
Huashan Hospital, Fudan University
Shanghai, China
The First Hospital of China Medical University
Shenyang, China
Tianjin Academy of Traditional Chinese Medicine Affiliated Hospital
Tianjin, China
Second Affiliated Hospital of Xi'an JiaoTong University
Xi'an, China
HOP l'Archet
Nice, France
HOP Saint-Louis
Paris, France
Fachklinik Bad Bentheim
Bad Bentheim, Germany
Universitätsklinikum Bonn AöR
Bonn, Germany
Universitätsklinikum Frankfurt
Frankfurt am Main, Germany
Klinikum der Universität München - Campus Innenstadt
München, Germany
Universitätsklinikum Münster
Münster, Germany
Klinikum Oldenburg AöR
Oldenburg, Germany
Universitätsklinikum Würzburg AÖR
Würzburg, Germany
General Hospital of Thessaloniki "Ippokrateio"
Thessaloniki, Greece
Istituto Clinico Humanitas
Rozzano (MI), Italy
Nagoya City University Hospital
Aichi, Nagoya, Japan
Kyushu Rosai Hospital
Fukuoka, Kitakyushu, Japan
Tokyo Medical University Ibaraki Medical Center
Ibaraki, Inashiki-gun, Japan
Saitama Medical University Hospital
Saitama, Iruma-gun, Japan
Tokyo Medical University Hachioji Medical Center
Tokyo, Hachioji, Japan
Tokyo Medical University Hospital
Tokyo, Shinjuku-ku, Japan
Hospital Raja Permaisuri Bainun
Ipoh, Malaysia
Hospital Sultanah Aminah
Johor Bahru, Malaysia
Hospital Sultan Ismail
Johor Bahru, Malaysia
Queen Elizabeth Hospital
Kota Kinabalu, Malaysia
Hospital Kuala Lumpur
Kuala Lumpur, Malaysia
Sarawak General Hospital
Kuching, Sarawak, Malaysia
Hospital Pakar Sultanah Fatimah
Muar town, Malaysia
Hospital Pulau Pinang
Pulau Pinang, Malaysia
Centro de Investigación de Enfermedades Autoinmunes S.C.
Guadalajara, Mexico
Hospital Universitario Dr Jose Eleuterio Gonzalez
Monterrey, Mexico
Showing 40 of 72 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.